Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers

Susmita Mondal, Debarshi Roy, Sayantani Sarkar Bhattacharya, Ling Jin, Deokbeom Jung, Song Zhang, Eleftheria Kalogera, Julie Staub, Yaxian Wang, Wen Xuyang, Ashwani Khurana, Jeremey Chien, Sucheta Telang, Jason Chesney, Gilles Tapolsky, Petras P Dzeja, Vijayalakshmi Shridhar

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Metabolic alterations are increasingly recognized as important novel anti-cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158-induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co-immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158-mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX-resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Carboplatin
Neoplasms
Paclitaxel
Fluorescent Antibody Technique
Therapeutics
Tumor Burden
Transmission Electron Microscopy
Immunoprecipitation
Ascites
Lactic Acid
Down-Regulation
Adenosine Triphosphate
Apoptosis
Glucose
Drug Therapy
Cell Line
bafilomycin A
Lipid Droplet Associated Proteins
fructose 2,6-diphosphate

Keywords

  • Chemoresistance
  • lipid droplet
  • lipophagy
  • ovarian and cervical cancer
  • PFKFB3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. / Mondal, Susmita; Roy, Debarshi; Sarkar Bhattacharya, Sayantani; Jin, Ling; Jung, Deokbeom; Zhang, Song; Kalogera, Eleftheria; Staub, Julie; Wang, Yaxian; Xuyang, Wen; Khurana, Ashwani; Chien, Jeremey; Telang, Sucheta; Chesney, Jason; Tapolsky, Gilles; Dzeja, Petras P; Shridhar, Vijayalakshmi.

In: International Journal of Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Mondal, S, Roy, D, Sarkar Bhattacharya, S, Jin, L, Jung, D, Zhang, S, Kalogera, E, Staub, J, Wang, Y, Xuyang, W, Khurana, A, Chien, J, Telang, S, Chesney, J, Tapolsky, G, Dzeja, PP & Shridhar, V 2018, 'Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers', International Journal of Cancer. https://doi.org/10.1002/ijc.31868
Mondal, Susmita ; Roy, Debarshi ; Sarkar Bhattacharya, Sayantani ; Jin, Ling ; Jung, Deokbeom ; Zhang, Song ; Kalogera, Eleftheria ; Staub, Julie ; Wang, Yaxian ; Xuyang, Wen ; Khurana, Ashwani ; Chien, Jeremey ; Telang, Sucheta ; Chesney, Jason ; Tapolsky, Gilles ; Dzeja, Petras P ; Shridhar, Vijayalakshmi. / Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. In: International Journal of Cancer. 2018.
@article{8813444fdd244ea8a775f10acbc39e05,
title = "Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers",
abstract = "Metabolic alterations are increasingly recognized as important novel anti-cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158-induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co-immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158-mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX-resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.",
keywords = "Chemoresistance, lipid droplet, lipophagy, ovarian and cervical cancer, PFKFB3",
author = "Susmita Mondal and Debarshi Roy and {Sarkar Bhattacharya}, Sayantani and Ling Jin and Deokbeom Jung and Song Zhang and Eleftheria Kalogera and Julie Staub and Yaxian Wang and Wen Xuyang and Ashwani Khurana and Jeremey Chien and Sucheta Telang and Jason Chesney and Gilles Tapolsky and Dzeja, {Petras P} and Vijayalakshmi Shridhar",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ijc.31868",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers

AU - Mondal, Susmita

AU - Roy, Debarshi

AU - Sarkar Bhattacharya, Sayantani

AU - Jin, Ling

AU - Jung, Deokbeom

AU - Zhang, Song

AU - Kalogera, Eleftheria

AU - Staub, Julie

AU - Wang, Yaxian

AU - Xuyang, Wen

AU - Khurana, Ashwani

AU - Chien, Jeremey

AU - Telang, Sucheta

AU - Chesney, Jason

AU - Tapolsky, Gilles

AU - Dzeja, Petras P

AU - Shridhar, Vijayalakshmi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Metabolic alterations are increasingly recognized as important novel anti-cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158-induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co-immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158-mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX-resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.

AB - Metabolic alterations are increasingly recognized as important novel anti-cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158-induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co-immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158-mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX-resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.

KW - Chemoresistance

KW - lipid droplet

KW - lipophagy

KW - ovarian and cervical cancer

KW - PFKFB3

UR - http://www.scopus.com/inward/record.url?scp=85055950890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055950890&partnerID=8YFLogxK

U2 - 10.1002/ijc.31868

DO - 10.1002/ijc.31868

M3 - Article

C2 - 30226266

AN - SCOPUS:85055950890

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -